Concepedia

Lola Luo

LL

Statistics

Publications

8

Citations

564

H-Index

8

Active since

2012

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

University of Pennsylvania

Lola Luo is an author at United States Food and Drug Administration specializing in medicine, pharmacology, and oncology.

Publications per year

2012–2019

8

Publications

8

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

Kelly J. Norsworthy, Lola Luo, Vicky Hsu et al. · Clinical Cancer Research · 2019 · 136 citations

, , +14

FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

Donna Przepiorka, Lola Luo, Sriram Subramaniam et al. · The Oncologist · 2019 · 132 citations · Full text

, , +10

FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy

Vishal Bhatnagar, Nicole Gormley, Lola Luo et al. · The Oncologist · 2017 · 77 citations · Full text

, , +13

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the <i>BRAF</i>V600 Mutation

Patricia O’Neal, Virginia E. Kwitkowski, Lola Luo et al. · The Oncologist · 2018 · 77 citations · Full text

, , +13

Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer

Dickran Kazandjian, Gideon M. Blumenthal, Lola Luo et al. · The Oncologist · 2016 · 74 citations · Full text

, , +14

1–5 of 8